NCT04888962

Brief Summary

This is a prospective observational case-control study comparing quantitative sensory testing data preformed during the third trimester of pregnancy and within 24 hours postpartum in women on medication-assisted treatment for opioid use disorder (OUD) to a gestational age-controlled cohort of women who do not have OUD. The primary goal is to measure elements of quantitative sensory testing including temperature pain threshold, temperature pain tolerance, and thermal and mechanical temporal summation for patients with opioid use disorder on medication-assisted treatment (MAT), and compare these results to gestational age matched controlled pregnant patients not on MAT.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 11, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 17, 2021

Completed
28 days until next milestone

Study Start

First participant enrolled

June 14, 2021

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2021

Completed
Last Updated

October 5, 2021

Status Verified

October 1, 2021

Enrollment Period

4 months

First QC Date

May 11, 2021

Last Update Submit

October 4, 2021

Conditions

Outcome Measures

Primary Outcomes (4)

  • QST Pain threshold

    Quantitative sensory testing is a pain sensitivity test in which the patient will tell the investigator the moment they first feel pain

    Completed at a time point antepartum/ before delivery

  • QST Pain Tolerance

    Quantitative sensory testing is a pain sensitivity test in which the patient will tell the investigator the moment the sensation becomes uncomfortable.

    Completed at a time point antepartum/ before delivery

  • QST Pain Threshold

    Quantitative sensory testing is a pain sensitivity test in which the patient will tell the investigator the moment they first feel pain

    Completed within 24 hours postpartum/ after delivery

  • QST Pain Tolerance

    Quantitative sensory testing is a pain sensitivity test in which the patient will tell the investigator the moment the sensation becomes uncomfortable.

    Completed within 24 hours postpartum/ after delivery

Study Arms (2)

Prospective cohort group

This cohort will include pregnant patients with a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.

Other: OUD

Control group

This cohort will include pregnant patients without a history of opiate use disorder (OUD) who will be followed from the third trimester of pregnancy until 24 hours postpartum.

Interventions

OUDOTHER

History of opioid use disorder.

Prospective cohort group

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study will enroll pregnant adults with opiate use disorder (on medication assisted therapy) who are currently in their third trimester.

You may qualify if:

  • Subjects that will be included in the prospective cohort group:
  • individuals at least 18 years of age
  • at least 28 weeks gestation (third trimester)
  • on medication-assisted treatment for opioid use disorder, including methadone or suboxone.
  • Patients who will be included in the control group:
  • individuals at least 18 years of age
  • at least 28 weeks gestation (third trimester)
  • have not been on been on opioids in the past 12 months.

You may not qualify if:

  • Those who are unable to participate in informed consent discussions,
  • Unable to give informed consent for any reason,
  • Not fluent in English (surveys are validated in English language)
  • Unable to participate fully in all study procedures for any reason including sensory deficits, scar tissue, or infection at any QST sites.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States

Location

MeSH Terms

Conditions

Opioid-Related Disorders

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Study Officials

  • Grace Lim, MD, MS

    University of Pittsburgh

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

May 11, 2021

First Posted

May 17, 2021

Study Start

June 14, 2021

Primary Completion

September 30, 2021

Study Completion

September 30, 2021

Last Updated

October 5, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

Locations